Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017
We aimed to compare the efficiency of the first dose of Hepatitis B (HB) vaccine: at Birth versus at 3 months and to evaluate the efficacy of HB vaccine. We conducted a cohort study in the governorate of Monastir. Vaccinated Cohort (VC) included populations receiving the first dose at 3 months (Prot...
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2020-01-01
|
| Series: | Libyan Journal of Medicine |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/19932820.2020.1809223 |
| _version_ | 1818405899232870400 |
|---|---|
| author | Wafa Dhouib Meriem Kacem Cyrine bennasrallah Manel Ben Fredj Hela Abroug Imen Zemni Souhir Chelly Issam Maalel Grira Said Samia Asma Belguith Sriha |
| author_facet | Wafa Dhouib Meriem Kacem Cyrine bennasrallah Manel Ben Fredj Hela Abroug Imen Zemni Souhir Chelly Issam Maalel Grira Said Samia Asma Belguith Sriha |
| author_sort | Wafa Dhouib |
| collection | DOAJ |
| description | We aimed to compare the efficiency of the first dose of Hepatitis B (HB) vaccine: at Birth versus at 3 months and to evaluate the efficacy of HB vaccine. We conducted a cohort study in the governorate of Monastir. Vaccinated Cohort (VC) included populations receiving the first dose at 3 months (Protocol 1), and at birth (HepB-BD) (Protocol 2). First dose was followed by at least two doses. We collected, from January 2000 to December 2017, cases diagnosed by serological markers (hepatitis B surface antigen (HBsAg) and anti-HBc). We calculated Absolute Risk (AR) per 100,000 PY and the Relative risk reduction (RRR). Twenty-five cases were notified among VC and 1501 cases among not vaccinated cohort (NVC). Twenty-three cases were notified among the cohort receiving the first dose at 3 months and two cases in Protocol 2. The AR per 100,000 PY was 5.67 (CI95%: 3.36–7.99) in Protocol 1 and 0.11 (CI95%: 0.001–0.26) in Protocol 2. The RRR was 77% (95% CI: 66; 85) in Protocol 1 and 99.4% (95% CI: 97.8; 99.9) in Protocol 2. We identified 4 HB cases for children aged between 5 and 11 who benefited from protocol 1 (born between 2000 and 2006) and zero cases for children of the same age group benefiting from protocol 2 (born between 2011 and 2017). The annual number of HB has decreased from 112 in 2000 to 48 in 2017. We predicted 40 new cases of HB in 2030. HepB-BD was 99.4% effective at preventing HB. The continuity of HepB-BD worldwide would achieve WHO‘s goal of eliminating HB as a threat to health by 2050. Abbreviations AR: Absolute Risk; ARR: Absolute Risk Reduction; G1: Group1; G2: Group2; HB: Hepatitis B; HepB-BD: Hepatitis B Birth Dose; MENA: Middle East and North Africa; NNV: Number Needed to Vaccine; HIV: Human Immunodeficiency Virus; NVC: Not Vaccinated Cohort; PY: Person Year; RRR: Relative Risk Reduction; RR: Relative Risk; VC: Vaccinated Cohort; WHO: World Health Organization |
| first_indexed | 2024-12-14T09:03:22Z |
| format | Article |
| id | doaj.art-50d55da1f923498297d80af4e9e52e51 |
| institution | Directory Open Access Journal |
| issn | 1993-2820 1819-6357 |
| language | English |
| last_indexed | 2024-12-14T09:03:22Z |
| publishDate | 2020-01-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Libyan Journal of Medicine |
| spelling | doaj.art-50d55da1f923498297d80af4e9e52e512022-12-21T23:08:45ZengTaylor & Francis GroupLibyan Journal of Medicine1993-28201819-63572020-01-0115110.1080/19932820.2020.18092231809223Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017Wafa Dhouib0Meriem Kacem1Cyrine bennasrallah2Manel Ben Fredj3Hela Abroug4Imen Zemni5Souhir Chelly6Issam Maalel7Grira Said Samia8Asma Belguith Sriha9University of MonastirUniversity of MonastirUniversity of MonastirUniversity of MonastirUniversity of MonastirUniversity of MonastirUniversity of MonastirMinister of HealthMinister of HealthUniversity of MonastirWe aimed to compare the efficiency of the first dose of Hepatitis B (HB) vaccine: at Birth versus at 3 months and to evaluate the efficacy of HB vaccine. We conducted a cohort study in the governorate of Monastir. Vaccinated Cohort (VC) included populations receiving the first dose at 3 months (Protocol 1), and at birth (HepB-BD) (Protocol 2). First dose was followed by at least two doses. We collected, from January 2000 to December 2017, cases diagnosed by serological markers (hepatitis B surface antigen (HBsAg) and anti-HBc). We calculated Absolute Risk (AR) per 100,000 PY and the Relative risk reduction (RRR). Twenty-five cases were notified among VC and 1501 cases among not vaccinated cohort (NVC). Twenty-three cases were notified among the cohort receiving the first dose at 3 months and two cases in Protocol 2. The AR per 100,000 PY was 5.67 (CI95%: 3.36–7.99) in Protocol 1 and 0.11 (CI95%: 0.001–0.26) in Protocol 2. The RRR was 77% (95% CI: 66; 85) in Protocol 1 and 99.4% (95% CI: 97.8; 99.9) in Protocol 2. We identified 4 HB cases for children aged between 5 and 11 who benefited from protocol 1 (born between 2000 and 2006) and zero cases for children of the same age group benefiting from protocol 2 (born between 2011 and 2017). The annual number of HB has decreased from 112 in 2000 to 48 in 2017. We predicted 40 new cases of HB in 2030. HepB-BD was 99.4% effective at preventing HB. The continuity of HepB-BD worldwide would achieve WHO‘s goal of eliminating HB as a threat to health by 2050. Abbreviations AR: Absolute Risk; ARR: Absolute Risk Reduction; G1: Group1; G2: Group2; HB: Hepatitis B; HepB-BD: Hepatitis B Birth Dose; MENA: Middle East and North Africa; NNV: Number Needed to Vaccine; HIV: Human Immunodeficiency Virus; NVC: Not Vaccinated Cohort; PY: Person Year; RRR: Relative Risk Reduction; RR: Relative Risk; VC: Vaccinated Cohort; WHO: World Health Organizationhttp://dx.doi.org/10.1080/19932820.2020.1809223efficiencyhepatitis bhumansvaccinationtunisia |
| spellingShingle | Wafa Dhouib Meriem Kacem Cyrine bennasrallah Manel Ben Fredj Hela Abroug Imen Zemni Souhir Chelly Issam Maalel Grira Said Samia Asma Belguith Sriha Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 Libyan Journal of Medicine efficiency hepatitis b humans vaccination tunisia |
| title | Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 |
| title_full | Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 |
| title_fullStr | Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 |
| title_full_unstemmed | Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 |
| title_short | Hepatitis B birth vaccination, cohort study, Tunisia 2000–2017 |
| title_sort | hepatitis b birth vaccination cohort study tunisia 2000 2017 |
| topic | efficiency hepatitis b humans vaccination tunisia |
| url | http://dx.doi.org/10.1080/19932820.2020.1809223 |
| work_keys_str_mv | AT wafadhouib hepatitisbbirthvaccinationcohortstudytunisia20002017 AT meriemkacem hepatitisbbirthvaccinationcohortstudytunisia20002017 AT cyrinebennasrallah hepatitisbbirthvaccinationcohortstudytunisia20002017 AT manelbenfredj hepatitisbbirthvaccinationcohortstudytunisia20002017 AT helaabroug hepatitisbbirthvaccinationcohortstudytunisia20002017 AT imenzemni hepatitisbbirthvaccinationcohortstudytunisia20002017 AT souhirchelly hepatitisbbirthvaccinationcohortstudytunisia20002017 AT issammaalel hepatitisbbirthvaccinationcohortstudytunisia20002017 AT grirasaidsamia hepatitisbbirthvaccinationcohortstudytunisia20002017 AT asmabelguithsriha hepatitisbbirthvaccinationcohortstudytunisia20002017 |